The total return for Tempus AI, Inc. (TEM) stock is -29.95% over the past 12 months vs. +24.11% for the S&P 500. So far it's up -16.02% this year. Includes price appreciation + reinvested dividends.
Tempus AI, Inc. (TEM) Compound Annual Growth Rates (CAGR) Summary
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (29.95%) | - | - | - | - | - |
| Total Return CAGR | (29.95%) | - | - | - | - | - |
| Revenue CAGR | +69.82% | +58.57% | +42.06% | - | - | - |
| Net Income CAGR | - | - | - | - | - | - |
| EPS CAGR | - | - | - | - | - | - |
| Free Cash Flow CAGR | - | - | - | - | - | - |
| Operating Cash Flow CAGR | - | - | - | - | - | - |
| Dividends CAGR | - | - | - | - | - | - |
CAGR Trends History
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
TEM Total Return CAGR Chart
Tempus AI, Inc. (TEM)
Annual Total Returns Comparison
| Year | Start Value | End Value | TEM Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | 146.71 | 123.20 | (16.02%) | +8.49% | (24.51%) |
| 2025 | 83.88 | 146.71 | +74.91% | +17.72% | +57.19% |
About Tempus AI, Inc.
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers "Insights," a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its "Trials" program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: "Next"; "Algos," a collection of algorithm-driven tests focused on oncology; "Hub," a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and "Lens," a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky